Biocartis and bioMérieux have signed an agreement to end their alliance for the development and commercialization of the integrated molecular biology system, Idylla (previously Apollo), in the field of microbiology molecular diagnostics. bioMérieux will return all rights on the Idylla platform to Biocartis.

In November 2010, Biocartis had entered into a strategic alliance with bioMérieux to develop and commercialize microbiology assays on Biocartis’ fully integrated molecular diagnostics platform Idylla. With the ending of the alliance, Biocartis has regained all the rights relating to the use of its platform in the microbiology field, and is free to explore new strategic options in that respect.

Rudi Pauwels, CEO of Biocartis, commented: “We will definitely keep microbiology assays in the menu of tests on the Idylla platform, either through internal developments or via a new partner.”

Biocartis aims to improve quality of life by providing direct access to personalized medicine to patients worldwide. Its goal is to advance medical treatment through the broad implementation of state-of-the-art personalized diagnostic tests performed close to the clinical decision-making point.